

Christopher R Flowers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6952683/publications.pdf>

Version: 2024-02-01

647
papers

26,253
citations

13099

68
h-index

8167

148
g-index

651
all docs

651
docs citations

651
times ranked

27816
citing authors

#	ARTICLE	IF	CITATIONS
1	Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 250-281.	329.8	1,287
2	Breast Cancer Screening for Women at Average Risk. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1599.	7.4	1,283
3	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 496-520.	1.6	971
4	PI3K γ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. <i>New England Journal of Medicine</i> , 2014, 370, 1008-1018.	27.0	956
5	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. <i>Journal of Clinical Oncology</i> , 2015, 33, 654-656.	1.6	911
6	American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5490-5505.	1.6	875
7	Genetic and Functional Drivers of Diffuse Large B-Cell Lymphoma. <i>Cell</i> , 2017, 171, 481-494.e15.	28.9	804
8	2016 US lymphoid malignancy statistics by World Health Organization subtypes. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 443-459.	329.8	791
9	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 2189-2204.	1.6	717
10	American Cancer Society lung cancer screening guidelines. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 106-117.	329.8	611
11	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2516-2522.	1.6	610
12	The genetic landscape of mutations in Burkitt lymphoma. <i>Nature Genetics</i> , 2012, 44, 1321-1325.	21.4	517
13	Genetic heterogeneity of diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1398-1403.	7.1	494
14	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 155-165.	1.6	488
15	Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 321-346.	329.8	481
16	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	1.4	382
17	Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2013, 31, 794-810.	1.6	364
18	Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 3043-3054.	1.6	357

#	ARTICLE	IF	CITATIONS
19	Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. <i>Blood</i> , 2004, 104, 961-968.	1.4	300
20	Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. <i>Blood</i> , 2004, 104, 1550-1558.	1.4	299
21	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363.	27.0	278
22	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 130-144.	2.1	265
23	Follicular Lymphoma in the United States: First Report of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1202-1208.	1.6	263
24	Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 1443-1453.	1.6	248
25	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. <i>Blood</i> , 2017, 129, 2224-2232.	1.4	243
26	Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 2787-2794.	1.6	230
27	Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. <i>Blood</i> , 2010, 116, e118-e127.	1.4	188
28	The Genetic Basis of Hepatosplenic T-cell Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 369-379.	9.4	163
29	Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). <i>Blood</i> , 2015, 126, 851-857.	1.4	161
30	International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. <i>Blood</i> , 2020, 135, 2041-2048.	1.4	158
31	Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3368-3375.	1.6	154
32	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Follicular Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 26-40.	2.1	151
33	Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3538-3546.	1.6	151
34	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	21.4	147
35	First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States-Based Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1112-1118.	1.6	144
36	Improving Outcomes for Patients With Diffuse Large B-Cell Lymphoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 393-408.	329.8	143

#	ARTICLE	IF	CITATIONS
37	Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. <i>Leukemia and Lymphoma</i> , 2008, 49, 2099-2107.	1.3	136
38	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2871-2883.	5.2	134
39	Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. <i>Journal of Clinical Oncology</i> , 2017, 35, 166-174.	1.6	131
40	Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. <i>Annals of Oncology</i> , 2014, 25, 2211-2217.	1.2	126
41	Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. <i>Cancer</i> , 2011, 117, 2530-2540.	4.1	125
42	A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy. <i>Journal of the American College of Surgeons</i> , 2003, 196, 385-393.	0.5	118
43	The whole-genome landscape of Burkitt lymphoma subtypes. <i>Blood</i> , 2019, 134, 1598-1607.	1.4	113
44	A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. <i>ISRN Hematology</i> , 2011, 2011, 1-14.	1.6	111
45	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
46	Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. <i>Leukemia and Lymphoma</i> , 2013, 54, 752-759.	1.3	98
47	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Diffuse Large B-Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 15-25.	2.1	98
48	The Role of Cost-Effectiveness Analysis in the Era of Pharmacogenomics. <i>Pharmacoeconomics</i> , 2004, 22, 481-493.	3.3	97
49	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.	1.6	97
50	Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5023-5030.	1.6	96
51	Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 3272-3276.	1.4	95
52	A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study. <i>Clinical Cancer Research</i> , 2010, 16, 5079-5086.	7.0	94
53	Effectiveness and cost analysis of salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. <i>Transfusion</i> , 2011, 51, 2175-2182.	1.6	93
54	Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4132-4139.	1.6	93

#	ARTICLE	IF	CITATIONS
55	Incidence Patterns and Outcomes for Hodgkin Lymphoma Patients in the United States. <i>Advances in Hematology</i> , 2011, 2011, 1-11.	1.0	90
56	Cost-Effectiveness of Immune Checkpoint Inhibition in <i>BRAF</i> Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1194-1202.	1.6	89
57	Treatment of Relapsed Acute Leukemia after Allogeneic Transplantation: A Single Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 116-123.	2.0	87
58	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 552-560.	1.6	87
59	Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K \hat{I} inhibitors and VIP antagonists. <i>Blood Advances</i> , 2018, 2, 210-223.	5.2	87
60	Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 460-467.e2.	0.4	86
61	Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3727-3732.	1.6	86
62	Examining Racial Disparities in Colorectal Cancer Care. <i>Journal of Psychosocial Oncology</i> , 2009, 27, 59-83.	1.2	81
63	Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. <i>BMC Health Services Research</i> , 2009, 9, 9.	2.2	81
64	Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. <i>Annals of Oncology</i> , 2013, 24, 441-448.	1.2	79
65	Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters. <i>Leukemia and Lymphoma</i> , 2010, 51, 1473-1477.	1.3	77
66	Disparities in the Early Adoption of Chemoimmunotherapy for Diffuse Large B-cell Lymphoma in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1520-1530.	2.5	76
67	Patterns of Failure in Advanced Stage Diffuse Large B-Cell Lymphoma Patients After Complete Response to R-CHOP Immunochemotherapy and the Emerging Role of Consolidative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 569-577.	0.8	76
68	Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 1811-1820.	1.4	75
69	150: A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 56.	2.0	74
70	Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. <i>Clinical Colorectal Cancer</i> , 2016, 15, 1-6.	2.3	72
71	Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 264-273.	2.5	71
72	Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. <i>Blood</i> , 2017, 129, 3037-3039.	1.4	68

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. <i>Haematologica</i> , 2017, 102, e156-e159.	3.5	68
74	Prescription Opioid Usage and Abuse Relationships: An Evaluation of State Prescription Drug Monitoring Program Efficacy. <i>Substance Abuse: Research and Treatment</i> , 2009, 3, SART.S2345.	0.9	67
75	Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. <i>Blood Advances</i> , 2020, 4, 5773-5784.	5.2	67
76	New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 531-544.	2.4	66
77	Racial variation in colorectal polyp and tumor location. <i>Journal of the National Medical Association</i> , 2007, 99, 723-8.	0.8	66
78	Nonmyeloablative Hematopoietic Cell Transplantation. <i>Annals of the New York Academy of Sciences</i> , 2001, 938, 328-339.	3.8	65
79	Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. <i>Lancet Haematology</i> , 2019, 6, e100-e109.	4.6	65
80	A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). <i>European Journal of Cancer</i> , 2016, 54, 11-17.	2.8	63
81	Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. <i>Annals of Oncology</i> , 2018, 29, 1932-1938.	1.2	63
82	Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 498-506.	0.4	62
83	Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. <i>Journal of Clinical Oncology</i> , 2017, 35, 3075-3082.	1.6	62
84	Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 153-162.	1.4	61
85	Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. <i>Annals of Oncology</i> , 2018, 29, 1822-1827.	1.2	61
86	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). <i>Journal of Clinical Oncology</i> , 2018, 36, 2593-2602.	1.6	59
87	CRP and ferritin in addition to the EASIX score predict CAR-related toxicity. <i>Blood Advances</i> , 2021, 5, 2799-2806.	5.2	57
88	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017, 92, 161-170.	4.1	56
89	PI3K γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. <i>Blood</i> , 2022, 139, 523-537.	1.4	56
90	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. <i>Blood</i> , 2022, 139, 1684-1693.	1.4	56

#	ARTICLE	IF	CITATIONS
91	Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2015, 121, 1800-1808.	4.1	54
92	Associations of Non-Hodgkin Lymphoma (NHL) Risk With Autoimmune Conditions According to Putative NHL Loci. <i>American Journal of Epidemiology</i> , 2015, 181, 406-421.	3.4	54
93	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) â€•outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patients. <i>American Journal of Hematology</i> , 2020, 95, 623-629.	4.1	54
94	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Peripheral T-Cell Lymphomas: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 66-75.	2.1	52
95	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	2.9	52
96	Charting the Future of Cancer Health Disparities Research: A Position Statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. <i>Cancer Research</i> , 2017, 77, 4548-4555.	0.9	52
97	Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. <i>Cancer</i> , 2016, 122, 2356-2363.	4.1	51
98	Secondâ€•line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. <i>British Journal of Haematology</i> , 2019, 184, 660-663.	2.5	51
99	Examining racial differences in diffuse large B-cell lymphoma presentation and survival. <i>Leukemia and Lymphoma</i> , 2013, 54, 268-276.	1.3	50
100	Disease characteristics, treatment patterns, prognosis, outcomes and lymphomaâ€•related mortality in elderly follicular lymphoma in the United States. <i>British Journal of Haematology</i> , 2015, 170, 85-95.	2.5	50
101	Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 353-361.	329.8	49
102	HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 303-311.	2.5	49
103	Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 271-279.	2.4	48
104	Insurance status is related to diffuse large B-cell lymphoma survival. <i>Cancer</i> , 2014, 120, 1220-1227.	4.1	47
105	Targeting the B cell receptor pathway in non-Hodgkin lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 513-522.	4.1	46
106	Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. <i>Journal of Clinical Oncology</i> , 2018, 36, 7507-7507.	1.6	45
107	Outcomes following watchful waiting for stage <scp>II</scp>â€•<scp>IV</scp> follicular lymphoma patients in the modern era. <i>British Journal of Haematology</i> , 2016, 172, 724-734.	2.5	44
108	A Decade of Progress in Lymphoma: Advances and Continuing Challenges. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 414-423.	0.4	43

#	ARTICLE	IF	CITATIONS
109	Necitumumab in Metastatic Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2015, 1, 1293.	7.1	43
110	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. <i>Blood Advances</i> , 2020, 4, 1038-1050.	5.2	43
111	Prophylactic Cholecystectomy in Transplant Patients: A Decision Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 965-972.	1.7	42
112	Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. <i>British Journal of Haematology</i> , 2016, 175, 892-903.	2.5	42
113	American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce. <i>Journal of Clinical Oncology</i> , 2017, 35, 2576-2579.	1.6	41
114	Cost-Effectiveness of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy. <i>Value in Health</i> , 2007, 10, 23-31.	0.3	40
115	Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States. <i>Cancer</i> , 2012, 118, 4842-4850.	4.1	40
116	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018, 124, 2306-2315.	4.1	40
117	Does the Addition of Involved Field Radiotherapy to High-Dose Chemotherapy and Stem Cell Transplantation Improve Outcomes for Patients With Relapsed/Refractory Hodgkin Lymphoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 175-180.	0.8	38
118	Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. <i>British Journal of Haematology</i> , 2017, 178, 72-80.	2.5	38
119	Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors. <i>Cancer Causes and Control</i> , 2018, 29, 551-561.	1.8	38
120	Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection. <i>Clinical Cancer Research</i> , 2019, 25, 6283-6294.	7.0	38
121	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 466-471.e1.	0.4	37
122	Clinical investigators as critical determinants in pharmaceutical innovation. <i>Nature Medicine</i> , 1997, 3, 136-143.	30.7	36
123	Bortezomib-containing induction regimens in transplant-eligible myeloma patients. <i>Cancer</i> , 2013, 119, 4119-4128.	4.1	36
124	Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma Using a Modern Dual-Field Rotational Technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 183-191.	0.8	36
125	Residential ambient benzene exposure in the United States and subsequent risk of hematologic malignancies. <i>International Journal of Cancer</i> , 2019, 145, 2647-2660.	5.1	36
126	Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 219-225.	2.3	35

#	ARTICLE	IF	CITATIONS
127	Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2017, 130, 2180-2185.	1.4	35
128	Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. <i>Nature Communications</i> , 2021, 12, 2877.	12.8	35
129	Surveillance Computed Tomography Scans for Patients With Lymphoma: Is the Risk Worth the Benefits?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 270-277.	0.4	34
130	The importance of immunization in cancer prevention, treatment, and survivorship. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 398-410.	329.8	34
131	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. <i>Cancer Research</i> , 2018, 78, 4086-4096.	0.9	34
132	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 202-212.	1.6	34
133	Using primary site as a predictor of survival in mantle cell lymphoma. <i>Cancer</i> , 2013, 119, 1570-1577.	4.1	33
134	The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. <i>Cancer</i> , 2014, 120, 1830-1837.	4.1	33
135	Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. <i>British Journal of Haematology</i> , 2021, 192, e38-e42.	2.5	33
136	Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1117-1121.	2.0	32
137	Pharmacokinetic-Directed High-Dose Busulfan Combined with Cyclophosphamide and Etoposide Results in Predictable Drug Levels and Durable Long-Term Survival in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1287-1294.	2.0	31
138	Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. <i>British Journal of Haematology</i> , 2012, 158, 608-614.	2.5	31
139	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mantle Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 76-86.	2.1	31
140	Unmet needs in the first-line treatment of follicular lymphoma. <i>Annals of Oncology</i> , 2017, 28, 2094-2106.	1.2	31
141	A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma. <i>Blood</i> , 2015, 126, 255-255.	1.4	31
142	Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma. <i>Value in Health</i> , 2015, 18, 189-197.	0.3	30
143	A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 569-575.e1.	0.4	30
144	Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918). <i>Blood</i> , 2015, 126, 811-811.	1.4	30

#	ARTICLE	IF	CITATIONS
145	Exploring Risk Factors for Follicular Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-13.	1.0	29
146	Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 852-857.	2.0	29
147	Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. <i>Blood</i> , 2017, 129, 561-564.	1.4	29
148	Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 2.	6.2	29
149	A Systematic Review and Meta-Analysis of Radioimmunotherapy Consolidation for Untreated Patients with Follicular Lymphoma (FL). <i>Blood</i> , 2011, 118, 101-101.	1.4	29
150	A Markov Model Assessing the Effectiveness and Cost-Effectiveness of FOLFOX Compared With FOLFIRI for the Initial Treatment of Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 49-55.	1.3	28
151	ACR Appropriateness Criteria®: Follow-Up of Hodgkin's Lymphoma. <i>Current Problems in Cancer</i> , 2010, 34, 211-227.	2.0	28
152	Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1700-1709.	1.3	28
153	Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. <i>Oncologist</i> , 2017, 22, 694-699.	3.7	27
154	Racial Differences in the Incidence and Outcomes for Patients with Hematological Malignancies. <i>Current Problems in Cancer</i> , 2007, 31, 182-201.	2.0	26
155	Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. <i>Supportive Care in Cancer</i> , 2013, 21, 2853-2860.	2.2	26
156	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018, 8, 73.	6.2	26
157	Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggregates. <i>Blood</i> , 2010, 116, 5285-5288.	1.4	25
158	Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma. <i>Cancer</i> , 2013, 119, 3309-3317.	4.1	25
159	Socioeconomic disparities in lymphoma. <i>Blood</i> , 2014, 123, 3530-3531.	1.4	25
160	Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: Implications for consolidation radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 961-965.	0.8	24
161	Predictors of Local Recurrence After Rituximab-Based Chemotherapy Alone in Stage III and IV Diffuse Large B-Cell Lymphoma: Guiding Decisions for Consolidative Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 107-112.	0.8	24
162	Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 250-255.	2.5	24

#	ARTICLE	IF	CITATIONS
163	Disparities in survival by insurance status in follicular lymphoma. <i>Blood</i> , 2018, 132, 1159-1166.	1.4	24
164	Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States. <i>British Journal of Haematology</i> , 2018, 183, 385-399.	2.5	24
165	Characteristics and Effectiveness of Rituximab (R) Maintenance Regimens Among US Patients Diagnosed with Follicular Lymphoma (FL) 2004-2007. <i>Blood</i> , 2011, 118, 3708-3708.	1.4	24
166	Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2867-2871.	5.2	24
167	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. <i>Lancet Haematology</i> , 2022, 9, e289-e300.	4.6	24
168	CD20-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional CD20 hits and outcomes with subsequent therapy. <i>Cancer</i> , 2017, 123, 4411-4418.	4.1	23
169	Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 114-124.e2.	0.4	23
170	Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 692-695.	2.5	23
171	Autograft vs Allograft Comparison in Pediatric Medial Patellofemoral Ligament Reconstruction. <i>Ochsner Journal</i> , 2019, 19, 96-101.	1.1	23
172	Maintenance Therapy in Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 507-513.	1.4	22
173	A black-white comparison of the quality of stage-specific colon cancer treatment. <i>Cancer</i> , 2010, 116, 713-722.	4.1	22
174	Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. <i>Transfusion</i> , 2010, 50, 2424-2431.	1.6	22
175	Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study. <i>Annals of Oncology</i> , 2015, 26, 2311-2317.	1.2	22
176	Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. <i>Leukemia and Lymphoma</i> , 2015, 56, 1295-1302.	1.3	22
177	Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. <i>American Journal of Hematology</i> , 2016, 91, 770-775.	4.1	22
178	Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≥ 65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2022, 23, 406-415.	10.7	22
179	Hepatitis C Reactivation in Patients Who Have Diffuse Large B-Cell Lymphoma Treated With Rituximab: A Case Report and Review of Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 379-384.	0.4	21
180	Lenalidomide in follicular lymphoma. <i>Blood</i> , 2020, 135, 2133-2136.	1.4	21

#	ARTICLE	IF	CITATIONS
181	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	5.2	21
182	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. <i>Medical Oncology</i> , 2016, 33, 48.	2.5	20
183	Making the Case for Improving Oncology Workforce Diversity. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 18-22.	3.8	20
184	Impact of the posttransplant lymphoproliferative disorder subtype on survival. <i>Cancer</i> , 2018, 124, 2327-2336.	4.1	20
185	Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. <i>Transfusion</i> , 2007, 47, 629-635.	1.6	19
186	A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. <i>Cancer</i> , 2012, 118, 3538-3548.	4.1	19
187	Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulating Factor Results in Fewer Plasmacytoid Dendritic Cells in the Graft and Enhanced Donor T Cell Engraftment with Th1 Polarization: Results from a Randomized Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 460-467.	2.0	19
188	Development of the Lymphoma Enterprise Architecture Database: A caBIG Silver Level Compliant System. <i>Cancer Informatics</i> , 2009, 8, CIN.S940.	1.9	18
189	Pharmacokinetic (PK) Comparison Of Intravenous Versus Oral Busulfan Conditioning Regimens for Acute Myeloid Leukemia (AML) And Myelodysplastic Syndrome (MDS) Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 154-155.	2.0	18
190	Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study. <i>Cancer</i> , 2013, 119, 4129-4136.	4.1	18
191	Temporal Changes in Plerixafor Administration and Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1393-1395.	2.0	18
192	Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors. <i>Bone Marrow Transplantation</i> , 2014, 49, 185-189.	2.4	18
193	Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 959-973.	2.2	18
194	Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. <i>Leukemia and Lymphoma</i> , 2019, 60, 894-903.	1.3	18
195	Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study. <i>Blood</i> , 2018, 132, 1683-1683.	1.4	18
196	Whole Genome and Exome Sequencing Defines The Genetic Landscape Of Hepatosplenic T-Cell Lymphoma. <i>Blood</i> , 2013, 122, 842-842.	1.4	18
197	Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, 2012, 87.	2.7	17
198	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1197-1205.	2.0	17

#	ARTICLE	IF	CITATIONS
199	Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. <i>Oncogene</i> , 2017, 36, 4224-4232.	5.9	17
200	PET-derived tumor metrics predict DLBCL response and progression-free survival. <i>Leukemia and Lymphoma</i> , 2019, 60, 1965-1971.	1.3	17
201	Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension. <i>Blood</i> , 2020, 136, 17-19.	1.4	17
202	Posttransplant Thrombopoiesis Predicts Survival in Patients Undergoing Autologous Hematopoietic Progenitor Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 895-904.	2.0	16
203	Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2008, 42, 529-534.	2.4	16
204	Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2122-2130.	1.3	16
205	ACR appropriateness Criteria® pediatric Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1305-1312.	1.5	16
206	ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. <i>Journal of the American College of Radiology</i> , 2014, 11, 1026-1033.e3.	1.8	16
207	Validation of cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and SÅ@zary syndrome. <i>Leukemia and Lymphoma</i> , 2016, 57, 2813-2819.	1.3	16
208	Microsimulation Modeling in Oncology. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-11.	2.1	16
209	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018, 93, 1543-1550.	4.1	16
210	Use of Rituximab with CHOP Chemotherapy Appears to Overcome Racial Disparities In Survival In Black Patients with Diffuse Large B Cell Lymphoma When Compared to CHOP Chemotherapy Alone.. <i>Blood</i> , 2010, 116, 1528-1528.	1.4	16
211	Next-generation surveillance strategies for patients with lymphoma. <i>Future Oncology</i> , 2015, 11, 1977-1991.	2.4	15
212	To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 244-255.	2.3	15
213	Identifying and Addressing Disparities in Survival Outcomes for Rural Patients With Cancer. <i>JAMA Network Open</i> , 2018, 1, e181243.	5.9	15
214	Genomeâ€defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large Bâ€cell lymphoma. <i>Cancer</i> , 2020, 126, 3493-3503.	4.1	15
215	Clustering of cutaneous Tâ€cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia. <i>Cancer</i> , 2020, 126, 1700-1707.	4.1	15
216	A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). <i>Blood</i> , 2020, 136, 40-41.	1.4	15

#	ARTICLE	IF	CITATIONS
217	Response and Survival Rates in Patients with Peripheral T-Cell Lymphoma Treated with Anthracycline-Based Regimens: A Comprehensive Meta-Analysis.. Blood, 2007, 110, 3452-3452.	1.4	15
218	Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g). Blood, 2013, 122, 1820-1820.	1.4	15
219	Assessing cost effectiveness of empirical and prophylactic therapy for managing leptospirosis outbreaks. Epidemiology and Infection, 2009, 137, 1323-1332.	2.1	14
220	Novel agents for diffuse large B-cell lymphoma. Expert Opinion on Investigational Drugs, 2011, 20, 669-680.	4.1	14
221	Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation. Annals of Lymphoma, 2017, 1, 1-1.	4.5	14
222	Cost burden of diffuse large B-cell lymphoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 645-661.	1.4	14
223	Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study. Leukemia and Lymphoma, 2019, 60, 1656-1667.	1.3	14
224	Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. Lancet Haematology,the, 2020, 7, e490-e497.	4.6	14
225	Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkinâ€™s Lymphoma (NHL): A Phase 2 Study.. Blood, 2005, 106, 17-17.	1.4	14
226	A Systematic Literature Review and Meta-Analysis of Radioimmunotherapy Consolidation for Patients With Untreated Follicular Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 393-399.	0.4	13
227	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Leukemia and Lymphoma, 2018, 59, 2862-2870.	1.3	13
228	Racial and Socioeconomic Disparities in Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e312-e320.	0.4	13
229	Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. Leukemia and Lymphoma, 2021, 62, 1077-1087.	1.3	13
230	Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study. Blood, 2020, 136, 45-47.	1.4	13
231	Relations Between Residential Proximity to EPA-Designated Toxic Release Sites and Diffuse Large B-Cell Lymphoma Incidence. Southern Medical Journal, 2016, 109, 606-614.	0.7	13
232	BiovaxIDâ„¢,ç idiotypic vaccination: active immunotherapy for follicular lymphoma. Expert Review of Vaccines, 2007, 6, 307-317.	4.4	12
233	Vinorelbine, Paclitaxel, Etoposide, Cisplatin, and Cytarabine (VTEPA) Is an Effective Second Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 657-663.	0.4	12
234	Optimal disease surveillance strategies in non-Hodgkin lymphoma. Hematology American Society of Hematology Education Program, 2014, 2014, 481-487.	2.5	12

#	ARTICLE	IF	CITATIONS
235	A phase III study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 539-546.	2.5	12
236	Resolving uncertainty in the spatial relationships between passive benzene exposure and risk of non-Hodgkin lymphoma. <i>Cancer Epidemiology</i> , 2016, 41, 139-151.	1.9	12
237	Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2017, 1, 2433-2443.	5.2	12
238	Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 513-523.	1.4	12
239	Patient and caregiver perceptions of lymphoma care and research opportunities: A qualitative study. <i>Cancer</i> , 2019, 125, 4096-4104.	4.1	12
240	A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients. <i>Cancer</i> , 2019, 125, 1837-1847.	4.1	12
241	The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. <i>Blood Advances</i> , 2020, 4, 1407-1418.	5.2	12
242	Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study. <i>Haematologica</i> , 2021, 106, 2774-2778.	3.5	12
243	Long-term follow-up of the PI3K inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. <i>Journal of Clinical Oncology</i> , 2016, 34, 7512-7512.	1.6	12
244	Refractory or Relapsed Hodgkin's Disease and Non-Hodgkin's Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2006, 12, 100-104.	2.9	11
245	Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2155-2162.	1.3	11
246	Racial differences in chronic lymphocytic leukemia. <i>Cancer</i> , 2013, 119, 3593-3595.	4.1	11
247	Dermato-Neuro Syndrome in a Patient Treated With Autologous Stem Cell Transplant for Scleromyxedema. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e213-e215.	0.4	11
248	The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2016, 57, 1876-1882.	1.3	11
249	Effective management strategies for patients with marginal zone lymphoma. <i>Future Oncology</i> , 2018, 14, 1213-1222.	2.4	11
250	Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. <i>Leukemia and Lymphoma</i> , 2018, 59, 888-895.	1.3	11
251	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021, 96, 1374-1384.	4.1	11
252	Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). <i>Journal of Clinical Oncology</i> , 2018, 36, 7547-7547.	1.6	11

#	ARTICLE	IF	CITATIONS
253	Initial management strategies for follicular lymphoma. <i>International Journal of Hematologic Oncology</i> , 2012, 1, 35-45.	1.6	10
254	Communicating Safe Outpatient Management of Fever and Neutropenia. <i>Journal of Oncology Practice</i> , 2013, 9, 207-210.	2.5	10
255	Efficacy and Tolerability of Anthracycline-Based Therapy in Elderly Patients With Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 270-277.	0.4	10
256	Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?. <i>Cancer</i> , 2017, 123, 3222-3225.	4.1	10
257	Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 651-657.	1.8	10
258	Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e115-e121.	0.4	10
259	Insurance status impacts overall survival in Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3225-3234.	1.3	10
260	Linking Environmental Exposures to Molecular Pathogenesis in Non-Hodgkin Lymphoma Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1844-1855.	2.5	10
261	Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study. <i>Blood</i> , 2019, 134, 4081-4081.	1.4	10
262	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. <i>Blood</i> , 2019, 134, 1525-1525.	1.4	10
263	A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States. <i>Blood</i> , 2011, 118, 97-97.	1.4	10
264	Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2013, 122, 85-85.	1.4	10
265	Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2014, 124, 1708-1708.	1.4	10
266	The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma. <i>Blood</i> , 2014, 124, 1722-1722.	1.4	10
267	Comparing the Cost-Effectiveness of the Triple Test Score to Traditional Methods for Evaluating Palpable Breast Masses. <i>Medical Care</i> , 2003, 41, 962-971.	2.4	9
268	Extracorporeal Photopheresis Therapy For Chronic Graft-Versus-Host Disease: Response Is Associated With Content Of Dendritic Cells And T-Cells In Peripheral Blood At Initiation Of Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 128-129.	2.0	9
269	ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 610-620.	1.3	9
270	Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. <i>Immunotherapy</i> , 2016, 8, 1335-1346.	2.0	9

#	ARTICLE	IF	CITATIONS
271	GIFT4 fusokine converts leukemic B cells into immune helper cells. <i>Journal of Translational Medicine</i> , 2016, 14, 106.	4.4	9
272	Identifying risk factors for B-cell lymphoma. <i>Blood</i> , 2016, 127, 10-11.	1.4	9
273	Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. <i>BMC Cancer</i> , 2017, 17, 198.	2.6	9
274	Sequencing of therapies in relapsed follicular lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 189-193.	2.5	9
275	Priorities for Rural Lymphoma Survivors: A Qualitative Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 47-52.e3.	0.4	9
276	The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. <i>Blood</i> , 2021, 138, 785-789.	1.4	9
277	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 753-753.	1.4	9
278	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019, 134, 69-69.	1.4	9
279	Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study. <i>Blood</i> , 2016, 128, 1213-1213.	1.4	9
280	Making the Case for Improving Oncology Workforce Diversity. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 18-22.	3.8	9
281	Integrating understanding of epidemiology and genomics in B-cell non-Hodgkin lymphoma as a pathway to novel management strategies. <i>Discovery Medicine</i> , 2016, 21, 181-8.	0.5	9
282	In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. <i>JCI Insight</i> , 2022, 7, .	5.0	9
283	Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 746-747.	2.0	8
284	Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy. <i>BMJ Open</i> , 2015, 5, e008350.	1.9	8
285	Next-generation prognostic assessment for diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2015, 11, 2443-2457.	2.4	8
286	B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. <i>Expert Review of Hematology</i> , 2016, 9, 553-561.	2.2	8
287	Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 1570-1580.	1.3	8
288	[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. <i>Leukemia and Lymphoma</i> , 2017, 58, 809-815.	1.3	8

#	ARTICLE	IF	CITATIONS
289	What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?. <i>Journal of Clinical Oncology</i> , 2018, 36, 3183-3185.	1.6	8
290	Novel immunotherapy approaches to follicular lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 194-199.	2.5	8
291	Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 418-427.	2.0	8
292	Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. <i>Cancer</i> , 2020, 126, 1235-1242.	4.1	8
293	Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. <i>JAMA Network Open</i> , 2020, 3, e2013935.	5.9	8
294	Microfluidic Platform to Transduce Cell Viability to Distinct Flow Pathways for High-Accuracy Sensing. <i>ACS Sensors</i> , 2021, 6, 3789-3799.	7.8	8
295	Phase 2 Study of Bortezomib Weekly or Twice Weekly Plus Rituximab in Patients with Follicular (FL) or Marginal Zone (MZL) Lymphoma: Final Results.. <i>Blood</i> , 2006, 108, 694-694.	1.4	8
296	Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 4591-4591.	1.4	8
297	Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2744-2744.	1.4	8
298	Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial. <i>Blood</i> , 2021, 138, 3525-3525.	1.4	8
299	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 821-833.	1.3	8
300	Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations. <i>American Journal of Hematology</i> , 2022, 97, 1044-1054.	4.1	8
301	Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 383-389.	1.3	7
302	Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 842-851.	1.3	7
303	The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. <i>Oncologist</i> , 2017, 22, 1415-1418.	3.7	7
304	Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4118.	4.1	7
305	Where to start? Upfront therapy for follicular lymphoma in 2018. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 185-188.	2.5	7
306	Clinical Implications of Febrile Neutropenia Guidelines in the Cancer Patient Population. <i>Journal of Oncology Practice</i> , 2019, 15, 25-26.	2.5	7

#	ARTICLE	IF	CITATIONS
307	Autologous stem cell transplantation for untreated transformed indolent Bâ€cell lymphoma in first remission: an international, multiâ€centre propensityâ€scoreâ€matched study. <i>British Journal of Haematology</i> , 2020, 191, 806-815.	2.5	7
308	Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States. <i>JCO Global Oncology</i> , 2020, 6, 1124-1133.	1.8	7
309	Stiffness based enrichment of leukemia cells using microfluidics. <i>APL Bioengineering</i> , 2020, 4, 036101.	6.2	7
310	Influenza Vaccination Rates Among Patients With a History of Cancer: Analysis of the National Health Interview Survey. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab198.	0.9	7
311	Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL). <i>Blood</i> , 2011, 118, 775-775.	1.4	7
312	Management Strategies for Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>European Oncology and Haematology</i> , 2012, 08, 123.	0.0	7
313	Rituximab Administration before Allogeneic HSCT Is Associated with Accelerated T Cell Reconstitution after Transplantation: Kinetic Evidence for a Graft-Versus-Leukemia Effect. <i>Blood</i> , 2014, 124, 3905-3905.	1.4	7
314	Considerations in the initial management of follicular lymphoma. <i>Community Oncology</i> , 2012, 9, S53-S60.	0.2	6
315	Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. <i>Community Oncology</i> , 2012, 9, S85-S92.	0.2	6
316	Plerixafor in combination with granulocyteâ€colonyâ€stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. <i>Transfusion</i> , 2015, 55, 2351-2357.	1.6	6
317	Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. <i>American Journal of Hematology</i> , 2021, 96, E137-E140.	4.1	6
318	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. <i>Cancer</i> , 2021, 127, 3390-3402.	4.1	6
319	Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 36-44.	0.8	6
320	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. <i>Blood</i> , 2018, 132, 1702-1702.	1.4	6
321	The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.. <i>Blood</i> , 2009, 114, 1689-1689.	1.4	6
322	The Addition of Bortezomib to Modified R-CHOP as Initial Therapy for Follicular NHL Results in High CR Rate and Is Well Tolerated.. <i>Blood</i> , 2009, 114, 3718-3718.	1.4	6
323	Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results. <i>Blood</i> , 2015, 126, 1538-1538.	1.4	6
324	Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8501-8501.	1.6	6

#	ARTICLE	IF	CITATIONS
325	Development of query strategies to identify a histologic lymphoma subtype in a large linked database system. <i>Cancer Informatics</i> , 2007, 3, 149-58.	1.9	6
326	American Society of Clinical Oncology 2007 Clinical Practice Guideline Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. <i>Journal of Oncology Practice</i> , 2007, 3, 326-329.	2.5	5
327	Development of Query Strategies to Identify a Histologic Lymphoma Subtype in a Large Linked Database System. <i>Cancer Informatics</i> , 2007, 3, 117693510700300.	1.9	5
328	Idiotype vaccine strategies for treatment of follicular lymphoma. <i>Future Oncology</i> , 2011, 7, 111-122.	2.4	5
329	Patterns of Social Support Among Lymphoma Patients Considering Stem Cell Transplantation. <i>Social Work in Health Care</i> , 2011, 50, 815-827.	1.6	5
330	Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect [®] CLL cohort study. <i>Leukemia and Lymphoma</i> , 2018, 59, 2327-2335.	1.3	5
331	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 55-70.	4.1	5
332	Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 300-309.e5.	0.4	5
333	Maintenance Therapy for Cutaneous T-cell Lymphoma After Total Skin Electron Irradiation: Evidence for Improved Overall Survival With Ultraviolet Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 757-767.e3.	0.4	5
334	Body mass index and survival of patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2671-2678.	1.3	5
335	Genetic Analysis of Plasmablastic Lymphomas in HIV (+) Patients Reveals Novel Driver Regulators of the Noncanonical NF- κ B Pathway. <i>Blood</i> , 2018, 132, 1565-1565.	1.4	5
336	The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs). <i>Blood</i> , 2011, 118, 3994-3994.	1.4	5
337	Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study. <i>Blood</i> , 2013, 122, 510-510.	1.4	5
338	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. <i>Blood</i> , 2016, 128, 3027-3027.	1.4	5
339	Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial. <i>Blood</i> , 2011, 118, 2988-2988.	1.4	5
340	Aesthetic preference and DSM-III-R personality disorders. <i>Personality and Individual Differences</i> , 1995, 18, 797-799.	2.9	4
341	ACR Appropriateness Criteria [®] on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II. <i>Journal of the American College of Radiology</i> , 2011, 8, 302-308.	1.8	4
342	Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 31-40.	3.1	4

#	ARTICLE	IF	CITATIONS
343	A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. <i>Transfusion</i> , 2013, 53, 76-84.	1.6	4
344	Rebirth of radiotherapy for elderly patients with diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2015, 56, 557-558.	1.3	4
345	Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 514-518.	0.4	4
346	CD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation. <i>Dermatology and Therapy</i> , 2016, 6, 251-263.	3.0	4
347	Successful Robotic Excision and Early Chemotherapy for Primary Cardiac Lymphoma. <i>Annals of Thoracic Surgery</i> , 2016, 102, 304-305.	1.3	4
348	ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 535-544.	1.3	4
349	A phase 2 trial of alisertib in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2268-2269.	1.3	4
350	Characterizing Lymphoma Incidence and Disparities for a Cancer Center Catchment Region. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 699-708.e5.	0.4	4
351	POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R-CHP VERSUS R-CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL. <i>Hematological Oncology</i> , 2019, 37, 68-70.	1.7	4
352	Safety and survival outcomes for bloodless transplantation in patients with myeloma. <i>Cancer</i> , 2019, 125, 185-193.	4.1	4
353	Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. <i>Leukemia and Lymphoma</i> , 2020, 61, 1380-1387.	1.3	4
354	Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radiology society appropriate use criteria. <i>Leukemia and Lymphoma</i> , 2021, 62, 1057-1065.	1.3	4
355	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. <i>Blood Advances</i> , 2021, 5, 1737-1745.	5.2	4
356	Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 7534-7534.	1.6	4
357	A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 74-83.	1.3	4
358	The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1361-1369.	1.3	4
359	Influenza Vaccination Documentation Rates During the First Year After Diagnosis of Diffuse Large B Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 239-243.	0.4	4
360	Abstract LB-272: Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma. <i>Cancer Research</i> , 2014, 74, LB-272-LB-272.	0.9	4

#	ARTICLE	IF	CITATIONS
361	Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. <i>Blood</i> , 2018, 132, 2892-2892.	1.4	4
362	Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≥ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial. <i>Blood</i> , 2020, 136, 35-36.	1.4	4
363	Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2007, 110, 3111-3111.	1.4	4
364	Black/White Differences in the Treatment and Outcomes of Diffuse Large B Cell Lymphoma: A Matched Cohort Analysis.. <i>Blood</i> , 2009, 114, 1392-1392.	1.4	4
365	Disparities in the Use of Chemo-Immunotherapy for Diffuse Large B-Cell Lymphoma in the United States.. <i>Blood</i> , 2009, 114, 897-897.	1.4	4
366	Age Differences in Disease Characteristics, Patterns of Care, and Outcomes of Follicular Lymphoma (FL) in the United States (US): Report From the National Lymphocare Study (NLCS). <i>Blood</i> , 2012, 120, 3708-3708.	1.4	4
367	Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups. <i>Blood</i> , 2016, 128, 1087-1087.	1.4	4
368	Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7511-7511.	1.6	4
369	Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma. <i>Blood</i> , 2019, 134, 19-19.	1.4	4
370	Improving our use and understanding of antibodies in B-cell lymphomas. <i>Oncology</i> , 2010, 24, 176-7.	0.5	4
371	ACR Appropriateness Criteria: Localized nodal indolent lymphoma. <i>Oncology</i> , 2013, 27, 786-94.	0.5	4
372	Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. <i>Journal of Clinical Oncology</i> , 2022, 40, 1949-1957.	1.6	4
373	B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1103-1110.	2.5	4
374	Idiotype vaccine strategies for improving outcomes in follicular lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1213-1223.	3.1	3
375	A randomized clinical trial comparing granulocyte colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation. <i>Transfusion</i> , 2011, 51, 1779-1783.	1.6	3
376	Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 725-727.	1.3	3
377	Matched Pair Comparison of Busulfan/Cyclophosphamide/Etoposide (BuCyE) to Carmustine/Etoposide/Cytarabine/Melphalan (BEAM) Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation (autoHCT) for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> . 2014. 20. S162.	2.0	3
378	Reply to age-related differences in quality of life among patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2015, 121, 2858-2859.	4.1	3

#	ARTICLE	IF	CITATIONS
379	Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital. <i>Journal of Stem Cell Research & Therapy</i> , 2016, 06, .	0.3	3
380	ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 384-395.	1.3	3
381	Reply to M.A. Slavin et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 1140-1141.	1.6	3
382	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019, 60, 940-946.	1.3	3
383	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	2.2	3
384	Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database. <i>Blood</i> , 2019, 134, 1610-1610.	1.4	3
385	Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) - a Phase II Clinical Trial. <i>Blood</i> , 2020, 136, 41-42.	1.4	3
386	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. <i>Blood</i> , 2007, 110, 949-949.	1.4	3
387	Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry. <i>Blood</i> , 2012, 120, 2072-2072.	1.4	3
388	Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. <i>Blood</i> , 2016, 128, 1102-1102.	1.4	3
389	a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2016, 128, 1776-1776.	1.4	3
390	Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics. <i>Blood</i> , 2016, 128, 1785-1785.	1.4	3
391	Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19554-e19554.	1.6	3
392	Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8532-8532.	1.6	3
393	Association of insurance status and race with overall survival among patients with cutaneous T-cell lymphoma: A National Cancer DataBase analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18624-e18624.	1.6	3
394	A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7589-TPS7589.	1.6	3
395	Association of geographic clustering of cutaneous T-cell lymphoma in the state of Georgia with environmental exposure to benzene and trichloroethylene.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1551-1551.	1.6	3
396	Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7544-7544.	1.6	3

#	ARTICLE	IF	CITATIONS
397	Incidence and Geographic Distribution of Adult Acute Leukemia in the State of Georgia. <i>Southern Medical Journal</i> , 2014, 107, 497-500.	0.7	3
398	Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 2085-2085.	1.4	3
399	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.	5.2	3
400	Strategies for Overcoming Disparities for Patients With Hematologic Malignancies and for Improving Enrollment on Clinical Trials. <i>Oncology</i> , 2020, 34, 216-223.	0.5	3
401	Additional Support for Consolidative Radiotherapy for Diffuse Large B Cell Lymphoma in the Modern Rituximab Era. <i>Acta Haematologica</i> , 2015, 134, 109-110.	1.4	2
402	Informatics Approaches to Address New Challenges in the Classification of Lymphoid Malignancies. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-9.	2.1	2
403	Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs. <i>Leukemia and Lymphoma</i> , 2019, 60, 2356-2364.	1.3	2
404	Biologic, clinical, and sociodemographic predictors of multi-agent systemic therapy for non-Hodgkin lymphoma in people living with HIV: a population-based investigation in the state of Georgia. <i>Leukemia and Lymphoma</i> , 2020, 61, 896-904.	1.3	2
405	Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect [®] CLL Registry. <i>EJHaem</i> , 2020, 1, 188-198.	1.0	2
406	SARS-CoV-2 in multiple myeloma: initial observation and management. <i>Leukemia and Lymphoma</i> , 2020, 61, 2763-2766.	1.3	2
407	Impact of maintenance rituximab in patients with <i>de novo</i> transformed indolent B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2985-2989.	1.3	2
408	Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 533-541.	0.4	2
409	Understanding and Addressing Disparities in Patients With Hematologic Malignancies: Approaches for Clinicians. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 351-357.	3.8	2
410	Using Informatics Tools to Characterize Precision Medicine Treatments for Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018, 132, 4801-4801.	1.4	2
411	Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL). <i>Blood</i> , 2019, 134, 5252-5252.	1.4	2
412	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). <i>Blood</i> , 2019, 134, 400-400.	1.4	2
413	Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 9-10.	1.4	2
414	A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg [®]) for Advanced MDS and Secondary or Relapsed AML. <i>Blood</i> , 2004, 104, 1814-1814.	1.4	2

#	ARTICLE	IF	CITATIONS
415	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. Blood, 2008, 112, 3332-3332.	1.4	2
416	Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2009, 114, 2947-2947.	1.4	2
417	Racial Disparities in Cell of Origin Among DLBCL Patients.. Blood, 2012, 120, 2686-2686.	1.4	2
418	Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia. Blood, 2012, 120, 3926-3926.	1.4	2
419	Comparing The Cost-Effectiveness Of Rituximab Maintenance (MR) and Radioimmunotherapy (RIT) Consolidation Therapy Following First-Line Chemo/Immunochemotherapies For Follicular Lymphoma. Blood, 2013, 122, 2923-2923.	1.4	2
420	A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2014, 124, 1725-1725.	1.4	2
421	Demographics By Age Group (AG) and Line of Therapy (LOT) in Chronic Lymphocytic Leukemia (CLL) Patients (Pts) Treated in US Practices from the Connect [®] CLL Registry. Blood, 2014, 124, 3338-3338.	1.4	2
422	Cost-Effectiveness of Subtype-Based Treatment Strategies for Diffuse Large B-Cell Lymphoma Patients (DLBCL). Blood, 2015, 126, 4476-4476.	1.4	2
423	Distress and Perceived Impact on Well-Being for Low- or Intermediate-Risk and High-Risk Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 5970-5970.	1.4	2
424	Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 6527-6527.	1.6	2
425	Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry.. Journal of Clinical Oncology, 2015, 33, 7013-7013.	1.6	2
426	Subsequent primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) in the modern treatment era.. Journal of Clinical Oncology, 2016, 34, 7543-7543.	1.6	2
427	Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma.. Journal of Clinical Oncology, 2016, 34, 7565-7565.	1.6	2
428	Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.. Journal of Clinical Oncology, 2017, 35, 7537-7537.	1.6	2
429	Impact on survival of surveillance imaging after first remission in follicular lymphoma.. Journal of Clinical Oncology, 2019, 37, 7536-7536.	1.6	2
430	Racial Differences in the Presentation and Outcomes of Diffuse Large B-Cell Lymphoma in the United States.. Blood, 2009, 114, 898-898.	1.4	2
431	Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS). Blood, 2010, 116, 1768-1768.	1.4	2
432	Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.. Blood, 2012, 120, 2728-2728.	1.4	2

#	ARTICLE	IF	CITATIONS
433	The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival. <i>Blood</i> , 2017, 130, 914-914.	1.4	2
434	A Data-Driven Approach to Define Parsimonious Eligibility Criteria in First-Line Clinical Trials for Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 3416-3416.	1.4	2
435	Abstract 2049: Cytokines associated with prolonged Cytopenia after axicabtagene ciloleucel in patients with refractory large B-cell lymphoma. <i>Cancer Research</i> , 2020, 80, 2049-2049.	0.9	2
436	New Challenges in the Management of Diffuse Large B-Cell Lymphoma. <i>Treatment Strategies Hematology</i> , 2012, 2, 68-73.	0.0	2
437	ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. <i>Oncology</i> , 2016, 30, 1099-103, 1106-8.	0.5	2
438	Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL. <i>Blood</i> , 2021, 138, 3572-3572.	1.4	2
439	Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion. <i>Blood</i> , 2021, 138, 1740-1740.	1.4	2
440	Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women With Cancer. <i>Oncology</i> , 2020, 34, 494-499.	0.5	2
441	Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors - Comprehensive Analysis of 396 Patients. <i>Blood</i> , 2020, 136, 32-33.	1.4	2
442	Reduced-intensity conditioning permits a significant graft vs leukemia (GvL) effect for acute leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 69-70.	2.0	1
443	Idiopathic secondary post-transplant thrombocytopenia (ISPT) following autologous hematopoietic progenitor cell transplantation (HPCT) is associated with transplantation of lower numbers of primitive hematopoietic progenitors. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 132.	2.0	1
444	Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma. <i>Cancer</i> , 2015, 121, 3387-3389.	4.1	1
445	A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 694-698.	0.4	1
446	Breast Cancer Screening for Women at Average Risk. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 153-155.	0.4	1
447	Outcomes in Mantle Cell Lymphoma for Elderly Patients Undergoing Autologous Stem Cell Transplant in CR1. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S265-S266.	2.0	1
448	Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors. <i>Bone Marrow Transplantation</i> , 2017, 52, 132-134.	2.4	1
449	Reply to C. Nabhan et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1864-1865.	1.6	1
450	Reply to A. Benedict et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 3086-3087.	1.6	1

#	ARTICLE	IF	CITATIONS
451	When to Choose Transplant in Follicular Lymphoma: Navigating a Complex Landscape. <i>Journal of Oncology Practice</i> , 2017, 13, 808-809.	2.5	1
452	Balancing patient value and payer cost in hematologic malignancies: can it be done?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 123-126.	1.4	1
453	The need to assess financial adverse events. <i>Lancet Haematology</i> , 2018, 5, e508-e509.	4.6	1
454	Intrathecal Central Nervous System Prophylaxis in Patients With Diffuse Large B-cell Lymphoma at an Academic Healthcare System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 89-94.	0.4	1
455	Retroperitoneal Follicular Dendritic Cell Sarcoma: A Case Report. <i>Advances in Radiation Oncology</i> , 2020, 5, 297-300.	1.2	1
456	A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1555-1564.	1.3	1
457	Perceptions of clinical care and research among African-American patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1860-1868.	1.3	1
458	Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	1.3	1
459	Survivor and Caregiver Perceptions of Lymphoma: A Qualitative Study. <i>Blood</i> , 2018, 132, 3561-3561.	1.4	1
460	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2157-2157.	1.4	1
461	Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. <i>Blood</i> , 2018, 132, 4197-4197.	1.4	1
462	Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3997-3997.	1.4	1
463	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3483-3483.	1.4	1
464	Systematic Review and Meta-Analysis of Radioimmunotherapy Regimens in Patients with Relapsed Follicular and Transformed Nonhodgkins Lymphomas.. <i>Blood</i> , 2005, 106, 3113-3113.	1.4	1
465	T Cell Reconstitution in First 200 Days Post Transplantation Predicts Long Term Survival in Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT).. <i>Blood</i> , 2006, 108, 3224-3224.	1.4	1
466	Determining the Benefits of Rituximab + Chemotherapy for Patients with Untreated Follicular Lymphoma: A Comprehensive Meta-Analysis.. <i>Blood</i> , 2006, 108, 3330-3330.	1.4	1
467	Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2011, 118, 1628-1628.	1.4	1
468	Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect ^Â CLL Disease Registry. <i>Blood</i> , 2011, 118, 2864-2864.	1.4	1

#	ARTICLE	IF	CITATIONS
469	Racial Disparities In Prediction Of 5-Year Overall Survival For Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Blood</i> , 2013, 122, 2922-2922.	1.4	1
470	PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study. <i>Blood</i> , 2013, 122, 4245-4245.	1.4	1
471	Disease Characteristics, Treatment Patterns, and Outcomes of Follicular Lymphoma in Patients 40 Years of Age and Younger: An Analysis from the National LymphoCare Study. <i>Blood</i> , 2014, 124, 3044-3044.	1.4	1
472	A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 1496-1496.	1.4	1
473	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. <i>Blood</i> , 2016, 128, 4196-4196.	1.4	1
474	Survival outcomes of plasma cell leukemia (PCL) in the United States: A SEER analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8609-8609.	1.6	1
475	Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6613-6613.	1.6	1
476	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 368-368.	1.6	1
477	Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 658-658.	1.6	1
478	Deferred treatment as a viable option for selected patients with mantle cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7567-7567.	1.6	1
479	Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10042-10042.	1.6	1
480	Determining the Benefits of Chemotherapy for Achieving Complete Response in Patients with Untreated Advanced Stage Follicular Lymphoma: A Systematic Review and Meta-Analysis.. <i>Blood</i> , 2005, 106, 290-290.	1.4	1
481	A Randomized Trial To Evaluate the Impact of Cytokines (G-CSF or GM + G-CSF) on Dendritic Cell and T-Cell Content and Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant.. <i>Blood</i> , 2006, 108, 3377-3377.	1.4	1
482	Cost-Effectiveness Analysis of a "Just-In-Time" Strategy of Salvage Plerixafor Administration for Poor-Mobilizing Patients Undergoing Autologous Transplant. <i>Blood</i> , 2010, 116, 2246-2246.	1.4	1
483	Strand-Specific Total RNA Sequencing Establishes the Complete Transcriptome and Alternative Splicing Repertoire in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2014, 124, 864-864.	1.4	1
484	Necitumumab in metastatic squamous non-small cell lung cancer (mSqNSCLC): Establishing a value-based cost.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6505-6505.	1.6	1
485	Prolonged Progression-Free Survival Is Possible in Patients with Diffuse Large B-Cell Lymphoma Receiving > 1 Salvage Therapies before Autologous Stem Cell Transplant. <i>Blood</i> , 2016, 128, 5825-5825.	1.4	1
486	The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study. <i>Blood</i> , 2018, 132, 5911-5911.	1.4	1

#	ARTICLE	IF	CITATIONS
487	Neurocognitive function and CNS integrity in adult survivors of childhood Hodgkin Lymphoma - a commentary on report from Krull and colleagues. <i>Translational Pediatrics</i> , 2013, 2, 1-2.	1.2	1
488	Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. <i>Blood</i> , 2021, 138, 3527-3527.	1.4	1
489	Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1408-1408.	1.4	1
490	Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 35-36.	1.4	1
491	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleuce (axi-cel) for Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020, 136, 17-18.	1.4	1
492	Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma. <i>Blood</i> , 2020, 136, 9-11.	1.4	1
493	Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 34-35.	1.4	1
494	Cyclosporin and the clinical investigator. <i>Nature Medicine</i> , 1997, 3, 590-590.	30.7	0
495	Treatment Options for Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Clinical Leukemia</i> , 2006, 1, 46-56.	0.2	0
496	In reply to Drs. Nieder and Andratschke. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1278.	0.8	0
497	Correlation of Patient Characteristics Including Age, Obesity, Gender and Race on the Metabolism of Busulfan. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S352-S353.	2.0	0
498	Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S191.	2.0	0
499	The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1089-1108.	2.4	0
500	Putting the "Activate"™ in Activated B Cell-like Diffuse Large B Cell Lymphoma: A Role for the Noncanonical NF- κ B Pathway. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S143.	0.4	0
501	Simplified Technique for Administration of High Dose Melphalan. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S291-S292.	2.0	0
502	Reply to treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2015, 121, 3748-3748.	4.1	0
503	Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 3842-3843.	1.6	0
504	Validation of Cutaneous Lymphoma International Prognostic Index (CLIPi) for Mycosis Fungoides and Sezary Syndrome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, S165-S166.	0.8	0

#	ARTICLE	IF	CITATIONS
505	Allogeneic Hematopoietic Cell Transplantation (HCT) for Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S200-S201.	2.0	0
506	Perspectives in Oncology Drug Pricing—Reply. <i>JAMA Oncology</i> , 2016, 2, 402.	7.1	0
507	Association of Complex Karyotype with Inferior Survival in Mantle Cell Lymphoma is Independent of Specific Cytogenetic Abnormalities. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S377.	0.4	0
508	Ethnic disparity in primary cutaneous CD30+ T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer database. <i>British Journal of Haematology</i> , 2018, 181, 721-722.	2.5	0
509	Reply to J.A. Talcott. <i>Journal of Clinical Oncology</i> , 2018, 36, 3174-3175.	1.6	0
510	Consolidative Radiation Therapy (RT) for Advanced Stage Hodgkin's Lymphoma (HL) May Improve Progression Free Survival Than ABVD Alone for Adult Patients.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, e280.	0.8	0
511	Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplant (ASCT). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S137-S138.	2.0	0
512	Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2255-2263.	1.3	0
513	Reply to H.J.A. Adams et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 526-527.	1.6	0
514	Prognostic Variables of Progression Free Survival in Mantle Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S23-S24.	2.0	0
515	Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 234-243.e10.	0.4	0
516	Prognostic Value of Disease Location in Secondary Central Nervous System Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e751-e752.	0.8	0
517	How Much Did We Impact the Risk of Second Malignancies in Patients with Classical Hodgkin Lymphoma by Changing the Treatment Paradigm?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, S141-S142.	0.8	0
518	How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?. <i>Leukemia and Lymphoma</i> , 2020, 61, 3283-3286.	1.3	0
519	A Randomized Trial to Evaluate the Impact of Cytokines on Dendritic Cell, T-Cell and T-Cell Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant: An Interim Analysis.. <i>Blood</i> , 2004, 104, 2854-2854.	1.4	0
520	Predictors of More Rapid Lymphoid Reconstitution after Allogeneic Transplantation.. <i>Blood</i> , 2004, 104, 3159-3159.	1.4	0
521	Patient Characteristics in CD 20+ and CD 20~ Adult Acute Lymphoblastic Leukemia (ALL): A Single Institution Analysis.. <i>Blood</i> , 2005, 106, 4523-4523.	1.4	0
522	Ex Vivo Fludarabine Selectively Depletes Human Naive T-Cell Subsets: A Step Toward Modifying Donor Lymphocyte Infusion.. <i>Blood</i> , 2005, 106, 1071-1071.	1.4	0

#	ARTICLE	IF	CITATIONS
523	Relapse Free Survival of Elderly AML Patients Is Comparable to That of Younger Adults When Treated with a Modified Dose Intensive Cytarabine Regimen.. Blood, 2005, 106, 4634-4634.	1.4	0
524	Decreased Incidence of Relapse in Patients with Acute Leukemia Transplanted from Matched Unrelated Donors: Induction of GvL.. Blood, 2005, 106, 2016-2016.	1.4	0
525	A Randomized Trial To Evaluate the Impact of Cytokines (G-CSF or GM + G-CSF) on Dendritic Cell and T-Cell Content and Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant.. Blood, 2005, 106, 1960-1960.	1.4	0
526	Infliximab for the Treatment of Chronic Graft Versus Host Disease.. Blood, 2006, 108, 2889-2889.	1.4	0
527	Mechanism for the Immuno-Suppression Activity of Pentostatin: Selective Apoptosis of Naive T Cell Subsets.. Blood, 2006, 108, 5160-5160.	1.4	0
528	Tolerability and Anti-Leukemic Activity of Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] in Advanced MDS and AML: Interim Analysis of Phase I/II Data.. Blood, 2006, 108, 1960-1960.	1.4	0
529	Patients Receiving Palifermin in Conjunction with Melphalan 200 Required Fewer Platelet Transfusions: Analysis of a Retrospective Cohort Study.. Blood, 2006, 108, 5261-5261.	1.4	0
530	Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study.. Blood, 2006, 108, 4989-4989.	1.4	0
531	Benefits of CHOP-14 Followed by Transplantation in Patients with Peripheral T-Cell Lymphoma.. Blood, 2006, 108, 4689-4689.	1.4	0
532	Impact of Revised International Working Group Criteria on Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.. Blood, 2006, 108, 3065-3065.	1.4	0
533	Therapeutic Drug Monitoring (TDM) of IV Busulfan in Patients with Severe Obesity.. Blood, 2007, 110, 1990-1990.	1.4	0
534	Examining Decision Making Styles in Patients with Lymphoma and Multiple Myeloma Considering Autologous Stem Cell Transplantation.. Blood, 2007, 110, 3322-3322.	1.4	0
535	The Effect of Rituximab on Mobilization with AMD3100 Plus G-CSF in Patients with Relapsed or Refractory NHL or HD.. Blood, 2007, 110, 1912-1912.	1.4	0
536	Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study. Blood, 2008, 112, 3644-3644.	1.4	0
537	Lymphoma and Whole Body CT Scan Mortality Risk. Blood, 2008, 112, 1321-1321.	1.4	0
538	Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease. Blood, 2008, 112, 1183-1183.	1.4	0
539	Examining Decision Making Styles in Patients with Sickle Cell Disease (SCD) Regarding Allogeneic Stem Cell Transplantation (ASCT). Blood, 2008, 112, 168-168.	1.4	0
540	Racial Disparities in Disease Presentation, Treatment, and Response Rates of Follicular Lymphoma (FL) in the United States (US): Report From the National LymphoCare Study (NLCS).. Blood, 2009, 114, 1381-1381.	1.4	0

#	ARTICLE	IF	CITATIONS
541	A Comprehensive Identification of the MicroRNA Transcriptome and Its Application in B Cell Malignancies.. Blood, 2009, 114, 2403-2403.	1.4	0
542	Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma. Blood, 2010, 116, 803-803.	1.4	0
543	Pharmacokinetic (PK)-Directed High Dose Intravenous Busulfan, Cyclophosphamide and Etoposide Produces Predictable Drug Exposure and Durable Long Term Survival In Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Blood, 2010, 116, 1359-1359.	1.4	0
544	Disease Characteristics and Patterns of Care In Elderly Patients (80+ years) with Follicular Lymphoma (FL) In the United States (US); Are Older Patients Treated Differently? Report From the National LymphoCare Study (NLCS). Blood, 2010, 116, 4152-4152.	1.4	0
545	Examining the Racial Disparities In Presentation and Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2010, 116, 1521-1521.	1.4	0
546	A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials., Blood, 2011, 118, 3954-3954.	1.4	0
547	Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma. Blood, 2011, 118, 433-433.	1.4	0
548	Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis. Blood, 2011, 118, 1959-1959.	1.4	0
549	Older Patients with Hodgkin Lymphoma (HL) Undergoing Autologous Stem Cell Transplantation for Relapsed/Refractory Disease Have Inferior Survival Compared to Younger Patients. Blood, 2011, 118, 4521-4521.	1.4	0
550	Patterns of Delivery of Chemoimmunotherapy to Patients with Follicular Lymphoma in the United States: Results of the National Lymphocare Study. Blood, 2012, 120, 3702-3702.	1.4	0
551	GM-CSF and IL-4 Derived Fusion Cytokine Reprograms Leukemic B-Cells to Anti-CLL Effectors. Blood, 2012, 120, 4606-4606.	1.4	0
552	Residence Proximity to Benzene Release Sites Is Associated with Increased Incidence of Non-Hodgkin Lymphoma.. Blood, 2012, 120, 2710-2710.	1.4	0
553	Consolidation with High Dose Therapy and Autologous Stem Cell Transplant Improves Survival for Patients with Mantle Cell Lymphoma. Blood, 2012, 120, 2006-2006.	1.4	0
554	ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom. Blood, 2012, 120, 898-898.	1.4	0
555	Certification and role of local pathologists for diffuse large B-cell lymphoma (DLBCL) subtyping and eligibility determination in the phase II PYRAMID study.. Journal of Clinical Oncology, 2013, 31, 8559-8559.	1.6	0
556	Outcomes of hematopoietic stem cell transplant recipients admitted to the medical intensive care unit.. Journal of Clinical Oncology, 2013, 31, 7035-7035.	1.6	0
557	Patterns of failure in advanced-stage diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP chemotherapy and the emerging role of consolidative radiotherapy.. Journal of Clinical Oncology, 2013, 31, 8546-8546.	1.6	0
558	Spatial Epidemiology Of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma In The State Of Georgia. Blood, 2013, 122, 1683-1683.	1.4	0

#	ARTICLE	IF	CITATIONS
559	Patterns Of Care and Outcomes Of Anthracyclines In Grade 3 Follicular Lymphoma (FL). Blood, 2013, 122, 4401-4401.	1.4	0
560	Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America. Blood, 2013, 122, 768-768.	1.4	0
561	Relationship Between Residential Proximity To Environmental Protection Agency (EPA) Designated Toxic Release Sites and The Risk Of Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2013, 122, 1684-1684.	1.4	0
562	Patterns and Outcomes Of First-Line Management Strategies In Older Adults With Low-Grade Follicular Lymphoma (FL). Blood, 2013, 122, 1805-1805.	1.4	0
563	Exome Sequencing Of African American Siblings With Activated, B-Cell Like Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 3014-3014.	1.4	0
564	Patterns Of First-Line Management Strategies In Older Adults With Follicular Lymphoma (FL). Blood, 2013, 122, 2983-2983.	1.4	0
565	Disease Characteristics, Patterns Of Care, and Outcomes Of Follicular Lymphoma (FL) In The Oldest Old. Blood, 2013, 122, 1817-1817.	1.4	0
566	A Proposed Prognostic Model For Overall Survival In The Oldest Old (>80 Years Old) Follicular Lymphoma Patients. Blood, 2013, 122, 3058-3058.	1.4	0
567	Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 6502-6502.	1.6	0
568	Differences in disease characteristics, treatment patterns, and outcomes between men (M) and women (W) with follicular lymphoma (FL): Prospective evaluation of 2,650 U.S. patients (pts).. Journal of Clinical Oncology, 2014, 32, 8550-8550.	1.6	0
569	Characteristics, treatments, and survival outcome of mantle cell lymphoma in women: A single center analysis.. Journal of Clinical Oncology, 2014, 32, e19559-e19559.	1.6	0
570	Peripheral T-cell lymphomas (PTCL) in the modern era: Prognosis and impact of therapy in a large U.S. multicenter cohort.. Journal of Clinical Oncology, 2014, 32, e19561-e19561.	1.6	0
571	A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkinâ€™s Lymphoma. Blood, 2014, 124, 4432-4432.	1.4	0
572	Disease Characteristics, Patterns of Care, and Survival in Very Elderly Patients with Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 4480-4480.	1.4	0
573	Insurance Status Impacts Survival in Follicular Lymphoma. Blood, 2014, 124, 1327-1327.	1.4	0
574	Determinants and Outcomes of the Use of Positron Emission Tomography (PET)-Staging in Newly Diagnosed Follicular Lymphoma (FL). Blood, 2014, 124, 2600-2600.	1.4	0
575	Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry. Blood, 2014, 124, 4672-4672.	1.4	0
576	Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkinâ€™s Lymphoma (NHL).. Journal of Clinical Oncology, 2015, 33, 8535-8535.	1.6	0

#	ARTICLE	IF	CITATIONS
577	Impact of racial residential segregation (RRS) on stage at diagnosis and survival after diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2015, 33, 6557-6557.	1.6	0
578	Abstract A11: GIFT4-reprogrammed leukemic B cells for CLL immunotherapy.. , 2015, , .		0
579	Complex Karyotype in Mantle Cell Lymphoma (MCL) Is Associated with Inferior Progression-Free Survival in Patients (pts) Receiving R-Hypercvad Followed By Autologous Stem Cell Transplant. Blood, 2015, 126, 5095-5095.	1.4	0
580	Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL [®] Cohort Study. Blood, 2015, 126, 3284-3284.	1.4	0
581	Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL [®] Registry. Blood, 2015, 126, 4483-4483.	1.4	0
582	Clinical Impact of Internet-Based Tools to Help Guide Therapeutic Decisions for Mantle Cell Lymphoma (MCL). Blood, 2015, 126, 4527-4527.	1.4	0
583	Deferred Treatment Is Associated with Improved Overall Survival in Patients with Newly Diagnosed Mantle Cell Lymphoma. Blood, 2015, 126, 2717-2717.	1.4	0
584	Suvmax in 18-Fluorodeoxyglucose PET/CT Potentially Predict the Estimation of a Positive Biopsy in Cases of Lymphoma. Blood, 2015, 126, 5043-5043.	1.4	0
585	Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL [®] Registry. Blood, 2015, 126, 5270-5270.	1.4	0
586	Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis.. Journal of Clinical Oncology, 2016, 34, 6518-6518.	1.6	0
587	Comparing the cost-effectiveness of immunotherapy strategies in BRAF wild-type advanced melanoma.. Journal of Clinical Oncology, 2016, 34, 6607-6607.	1.6	0
588	Assessing the Feasibility of Pathology Informatics Approaches for Subtyping Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2016, 128, 5408-5408.	1.4	0
589	Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features. Blood, 2016, 128, 513-513.	1.4	0
590	Use of Metabolic Tumor Volume (MTV) in Patients with Mantle Cell Lymphoma. Blood, 2016, 128, 5321-5321.	1.4	0
591	Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect [®] CLL Registry. Blood, 2016, 128, 3581-3581.	1.4	0
592	Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect [®] CLL Registry. Blood, 2016, 128, 5941-5941.	1.4	0
593	Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies. Blood, 2016, 128, 103-103.	1.4	0
594	Sociodemographic Factors Predict Medical Conditions Among Five-Year Survivors of Adolescent and Young Adult Hodgkin Lymphoma. Blood, 2016, 128, 693-693.	1.4	0

#	ARTICLE	IF	CITATIONS
595	CD30 Expression Is Not Acquired at Time of Relapse in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4225-4225.	1.4	0
596	Characterizing Autoimmune Disease-Associated Diffuse Large B Cell Lymphoma in a SEER-Medicare Cohort. <i>Blood</i> , 2016, 128, 4214-4214.	1.4	0
597	An Evaluation of the Role of Surveillance Imaging in Mantle Cell Lymphoma in First Remission. <i>Blood</i> , 2016, 128, 1799-1799.	1.4	0
598	MYC+ relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7541-7541.	1.6	0
599	Interim metabolic tumor volume to predict response in diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7557-7557.	1.6	0
600	A multistate model for follicular lymphoma (FL) patients (pts) who experience early progression.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18164-e18164.	1.6	0
601	Insurance Status Impacts Survival in Burkitt Lymphoma. <i>Blood</i> , 2017, 130, 916-916.	1.4	0
602	Effect of physical activity (PA) before and after diagnosis on overall survival (OS) for patients (pts) with lymphoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 95-95.	1.6	0
603	Racial and socioeconomic disparities in mantle cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18610-e18610.	1.6	0
604	A meta-analysis on ABVD administration in HIV+ patients with advanced stage Hodgkin's lymphoma (HL).. <i>Journal of Clinical Oncology</i> , 2018, 36, e19522-e19522.	1.6	0
605	ILyAD (Indolent Lymphoma and Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7587-TPS7587.	1.6	0
606	Outcomes in non-Hodgkin lymphoma by Latino country-of-origin (COO).. <i>Journal of Clinical Oncology</i> , 2018, 36, e18727-e18727.	1.6	0
607	Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2018, 36, e19509-e19509.	1.6	0
608	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018, 132, 4153-4153.	1.4	0
609	Evaluation of Maintenance Therapy in Cutaneous T-Cell Lymphoma Patients Receiving Total Skin Electron Beam Radiation Therapy. <i>Blood</i> , 2018, 132, 1639-1639.	1.4	0
610	Circulating B Cell Subsets from Untreated Diffuse Large B Cell Lymphoma (DLBCL) Patients Resemble Those of Patients with Autoimmune Disease. <i>Blood</i> , 2018, 132, 4221-4221.	1.4	0
611	Characterization of Clinical Features and Survival of Patients with Autoimmune-Associated Diffuse Large B Cell Lymphoma in a Large Institutional Cohort. <i>Blood</i> , 2018, 132, 4233-4233.	1.4	0
612	Increased Charlson Comorbidity Index (CCI) Is Not Associated with Inferior Clinical Outcomes in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018, 132, 5327-5327.	1.4	0

#	ARTICLE	IF	CITATIONS
613	Utilization of a Novel Method of Detection of CD30 Expression in Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 2978-2978.	1.4	0
614	Influenza Vaccination Rates during the First Year after Diagnosis of Diffuse Large B Cell Lymphoma. Blood, 2018, 132, 4820-4820.	1.4	0
615	Priorities for Rural Lymphoma Survivors: An Exploratory Study. Blood, 2018, 132, 4789-4789.	1.4	0
616	Exploring the Needs and Priorities of Black Patients with Lymphoma: A Qualitative Study. Blood, 2019, 134, 5815-5815.	1.4	0
617	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. Blood, 2019, 134, 5891-5891.	1.4	0
618	A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group. Blood, 2019, 134, 2812-2812.	1.4	0
619	Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma. Blood, 2019, 134, 410-410.	1.4	0
620	Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab. Blood, 2019, 134, 4008-4008.	1.4	0
621	Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma. Blood, 2019, 134, 414-414.	1.4	0
622	Abstract B092: Epstein-Barr virus prevalence in classical Hodgkin lymphoma tumors by race/ethnicity in a multiethnic U.S. population. , 2020, , .		0
623	Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. Blood, 2021, 138, 2463-2463.	1.4	0
624	Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. Blood, 2021, 138, 4536-4536.	1.4	0
625	Variance in Practice between Experts and Oncology Healthcare Professionals for Follicular Lymphoma: Analysis of an Online Treatment Decision Tool. Blood, 2021, 138, 1922-1922.	1.4	0
626	Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. Blood, 2021, 138, 3526-3526.	1.4	0
627	Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. Blood, 2021, 138, 1448-1448.	1.4	0
628	Realmind: A Prospective, Multicenter, Observational Study of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second- or Third-Line Therapy and Not Receiving Autologous Stem Cell Transplant. Blood, 2021, 138, 5010-5010.	1.4	0
629	Sirp ⁺ and CSF1R Positive Tissue Macrophages Are Increased in Patients with Follicular Lymphoma Who Relapse after Frontline Lenalidomide and Rituximab. Blood, 2021, 138, 1336-1336.	1.4	0
630	A Phase 1/1b Open-Label, Multicenter, Two-Part Study of SETD2 Inhibitor EZM0414 in Patients with Relapsed/Refractory Multiple Myeloma or Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 1679-1679.	1.4	0

#	ARTICLE	IF	CITATIONS
631	Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. <i>Blood</i> , 2021, 138, 338-338.	1.4	0
632	Connect Â® Lymphoma Disease Registry: A US-Based, Prospective, Observational Cohort Study. <i>Blood</i> , 2021, 138, 1460-1460.	1.4	0
633	Immune-Depleted Tumor Microenvironment Signature Is Associated with BTK Inhibitor Resistance in Mantle Cell Lymphoma. <i>Blood</i> , 2021, 138, 1321-1321.	1.4	0
634	Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 3870-3870.	1.4	0
635	Modernizing Eligibility Criteria in First-Line Clinical Trials for Diffuse Large B-Cell Lymphoma: Consensus Recommendations Using a Modified Delphi-Method Survey. <i>Blood</i> , 2020, 136, 49-50.	1.4	0
636	Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
637	Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 39-39.	1.4	0
638	Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
639	Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 41-42.	1.4	0
640	Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. <i>Blood</i> , 2020, 136, 10-12.	1.4	0
641	Body Mass Index and Survival of Patients with Lymphoma. <i>Blood</i> , 2020, 136, 2-3.	1.4	0
642	Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. <i>Blood</i> , 2020, 136, 27-28.	1.4	0
643	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
644	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
645	Abstract 4206: Examining genetic ancestry in diffuse large B-cell lymphoma (DLBCL). , 2019, , .		0
646	Abstract 5053: Epstein-Barr virus prevalence in classical Hodgkin lymphoma tumors is explained by histologic subtype, not race/ethnicity in a multiethnic US population. , 2019, , .		0
647	The impact of sequence of therapy for older patients with follicular lymphoma: SEER-Medicare analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.4	0